Fintel reports that on March 7, 2025, Scotiabank initiated coverage of Sarepta Therapeutics (NasdaqGS:SRPT) with a Sector ...

Biotech company Sarepta Therapeutics (NASDAQ:SRPT) announced in Q4 CY2024, with sales up 65.9% year on year to $658.4 million ...

Oppenheimer Asset Management Inc. decreased its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 8.5% during the fourth quarter, HoldingsChannel.com reports. The ...

EST Sarepta (SRPT) files automatic mixed securities shelfDiscover the Best Stocks and Maximize Your Portfolio: See what stocks are ...

Sarepta Therapeutics (NASDAQ:SRPT – Free Report) had its price target reduced by Royal Bank of Canada from $165.00 to $161.00 ...

Biotech company Sarepta Therapeutics (NASDAQ:SRPT) will be reporting results tomorrow after the bell. Here’s what you need to ...

The price trend for Sarepta Therapeutics (SRPT) has been bearish lately and the stock has lost 9% over the past four weeks. However, the formation of a hammer chart pattern in its last trading ...

Good afternoon, and welcome to the Sarepta Therapeutics fourth quarter and full year 2024 financial results conference call.

In this article, we are going to take a look at where Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stands against the other healthcare stocks. McKinsey reported that, since 2019, the US healthcare ...

Reports Q4 revenue $658.4M, consensus $631.03M. “2024 performance represented the fruition of our multi-year strategy to become a ...